Search Results - "Weems, Garry"

Phase 1 Open-Label, Multicenter Study of First-in-Class RORγ Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity by Mahalingam, Devalingam, Wang, Judy S, Hamilton, Erika P, Sarantopoulos, John, Nemunaitis, John, Weems, Garry, Carter, Laura, Hu, Xiao, Schreeder, Marshall, Wilkins, H Jeffrey

“…Transcription factor retinoic acid receptor-related orphan receptor γ (RORγ) regulates type 17 effector T-cell differentiation and function and is key to…”
Get full text

Abstract CT132: Safety and dose selection for LYC-55716, a first-in-class RORγ agonist to treat solid tumors: Phase I results from an open-label, multicenter Phase I/IIa trial by Mahalingam, Devalingam, Wang, Judy S., Hamilton, Erika P., Weems, Garry, Schreeder, Marshall, Wilkins, H. Jeffrey

“…Abstract Background: LYC-55716, a first-in-class, oral, small-molecule agonist of the retinoic acid receptor-related orphan receptor γ (RORγ), is under…”
Get full text

A phase 1b trial of RORγ agonist LYC-55716 in combination with pembrolizumab to evaluate safety, efficacy, and immune biomarker profiles in patients with metastatic non-small cell lung cancer by Camidge, D. Ross, Gadgeel, Shirish M., Weems, Garry Alan, Wilkins, H. Jeffrey, Johnson, Melissa Lynne

“…Abstract only…”
Get full text

Abstract 5566: LYC-55716, a first-in-class RORγ agonist: Rationale and preclinical data to support clinical combinations with established immunotherapies by Hu, Xiao, Liu, Xikui, Li, Hongxiu, Weems, Garry, Zawidzka, Elizabeth, Gao, Yilin, Wilkins, H. Jeffrey, Carter, Laura

“…Abstract The retinoic acid-related orphan receptor γt (RORγt) is a nuclear receptor transcription factor that acts as an immune cell master control switch…”
Get full text

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Tumor selection and evaluation of renal cell and bladder cancer for inclusion in phase 2a expansion by Hu, Xiao, Liu, Xikui, Li, Hongxiu, Zawidzka, Elizabeth, Weems, Garry Alan, Gao, Yilin, Fox, Brian, Wilkins, H. Jeffrey, Carter, Laura

“…Abstract only 424 Background: The master transcription factor retinoic acid receptor–related orphan receptor γt (RORγ) controls Type 17 effector T cell…”
Get full text

RORγ agonist LYC-55716, a novel small molecule immunotherapy: Rationale for clinical evaluation in non-small cell lung cancer based on translational and bioinformatic evaluation by Carter, Laura, Liu, Xikui, Li, Hongxiu, Zawidzka, Elizabeth, Gao, Yilin, Fox, Brian, Weems, Garry, Wilkins, H. Jeffrey, Hu, Xiao

“…Abstract only 171 Background: Retinoic acid receptor–related orphan receptor γ (RORγ) agonists modulate immune cell gene expression to enhance effector…”
Get full text

Lyc-55716: A novel small-molecule RORγ agonist immuno-oncology agent: Rationale for tumor selection and clinical evaluation of gastric and esophageal carcinoma in phase 2a expansion by Weems, Garry Alan, Hu, Xiao, Liu, Xikui, Li, Hongxiu, Bogdan, Madhumita, Gao, Yilin, Fox, Brian, Wilkins, H. Jeffrey, Carter, Laura

“…Abstract only 67 Background: Type 17 effector T cell differentiation and function are regulated by the master transcription factor retinoic acid…”
Get full text

A phase 2A open-label, multicenter trial of the safety and efficacy of LYC-55716, a first-in-class oral, small-molecule RORγ agonist to treat select solid tumors by Kelly, Karen, Johnson, Melissa Lynne, Mahalingam, Devalingam, Liu, Stephen V., Uronis, Hope Elizabeth, Wu, Christina, Carter, Laura, Hu, Xiao, Weems, Garry Alan, Wilkins, H. Jeffrey, Duska, Linda R.

“…Abstract only…”
Get full text

Results of a phase II study of pralatrexate in patients with advanced/metastatic relapsed transitional cell carcinoma of the urinary bladder by Loriot, Yohann, Fizazi, Karim, Carles, Joan, Weems, Garry Alan, Chance, Lacey, Agarwal, Neeraj

“…Abstract only 4574 Background: Antifolate agents have demonstrated activity in transitional cell carcinoma (TCC), a disease with very poor outcomes in advanced…”
Get full text

Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy by Kelly, Karen, Azzoli, Christopher G, Zatloukal, Petr, Albert, István, Jiang, Peter Y Z, Bodkin, David, Pereira, José Rodrigues, Juhász, Erzsébet, Iannotti, Nicholas O, Weems, Garry, Koutsoukos, Tony, Patel, Jyoti D

“…Pralatrexate, a folate analogue targeting dihydrofolate reductase, has antitumor activity in non-small-cell lung cancer (NSCLC). This randomized phase 2b trial…”
Get more information

A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors by Alexandre, Jérôme, Kahatt, Carmen, Bertheault-Cvitkovic, Frédérique, Faivre, Sandrine, Shibata, Stephen, Hilgers, Werner, Goldwasser, François, Lokiec, François, Raymond, Eric, Weems, Garry, Shah, Ajit, MacDonald, John R, Cvitkovic, Esteban

“…To determine the maximum tolerated dose (MTD), recommended dose, dose limiting toxicities (DLT), safety and pharmacokinetics of irofulven combined with…”
Get full text

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer by Seiden, Michael V., Gordon, Alan N., Bodurka, Diane C., Matulonis, Ursula A., Penson, Richard T., Reed, Eddie, Alberts, Dave S., Weems, Garry, Cullen, Michael, McGuire, William P.

“…To determine the safety and efficacy of a novel illudin S derivative, irofulven (MGI-114), in patients with recurrent ovarian cancer who had received extensive…”
Get full text

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors by Hilgers, Werner, Faivre, Sandrine, Chieze, Stéphanie, Alexandre, Jérôme, Lokiec, François, Goldwasser, François, Raymond, Eric, Kahatt, Carmen, Taamma, Abdelkrim, Weems, Garry, MacDonald, John R, Misset, Jean-Louis, Cvitkovic, Esteban

“…To determine maximum tolerated dose (MTD), recommended dose, safety and pharmacokinetics of irofulven combined with cisplatin in advanced solid tumor patients…”
Get full text